Environment &
Food & Beverage
Cosmetics
Life Sciences
Metal & Mining Industry
Petrochemical & General Chemistry
Automotive Related & Interior Materials
InertSearch (Application Library)
Index
Application
LC
Document No. Index
LB013 - 100 of Application List
| No. | Description | Column |
|---|---|---|
| LB013 | Analysis of Iohexol and Iopamidol | InertSustain C18 |
| LB014 | Analysis of Ergosterol(InertSustain C18) | InertSustain C18 |
| LB015 | Analysis of Ergosterol(Inertsil ODS-4) | Inertsil ODS-4 |
| LB016 | Analysis of Iminoctadine | InertSustain C18 |
| LB017 | Analysis of Furosemide(Under the Condition of Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB018 | Analysis of Potassium ferricyanide and Potassium ferrocyanide | InertSustain C18 |
| LB019 | Analysis of Losartan Potassium and Hydrochlorothiazide | Inertsil C8-4 |
| LB020 | Analysis of Losartan Potassium and Hydrochlorothiazide | InertSustain C8 |
| LB021 | Analysis of Valsartan and Hydrochlorothiazide | InertSustain C18 |
| LB022 | Analysis of Losartan potassium and Valsartan | InertSustain C18 |
| LB023 | Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) | InertSustain C18 |
| LB024 | Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) | InertSustain C18 |
| LB025 | Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Hydrate) | InertSustain C18 |
| LB026 | Analysis of Pitavastatin Calcium | InertSustain C18 |
| LB027 | Analysis of Pitavastatin Calcium | InertSustain C18 |
| LB028 | Analysis of Pitavastatin Calcium | InertSustain C18 |
| LB029 | Analysis of Pitavastatin Calcium | InertSustain C18 |
| LB030 | Analysis of Vitamin K (InertSustain C8) | InertSustain C8 |
| LB031 | Analysis of Preservatives and Sweetener | InertSustain Phenyl |
| LB032 | Analysis of Malto oligosugars | InertSustain NH2 |
| LB033 | Analysis of Vitamin E | InertSustain NH2 |
| LB034 | Analysis of Nucleotides | InertSustain NH2 |
| LB035 | Analysis of Terbinafine HCl (InertSustain C18) (Under the Condition of Japanese Pharmacopoeia) | InertSustain C18 |
| LB036 | Analysis of Terbinafine HCl (Inertsil ODS-3) (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB037 | Analysis of Terbinafine HCl (Inertsil ODS-4) (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB038 | Analysis of Chlorantraniliprole (InertSustain C18) | InertSustain C18 |
| LB039 | Analysis of Phospholipids (InertSustain C18) | InertSustain C18 |
| LB040 | Analysis of Phospholipids (InertSustain C8) | InertSustain C8 |
| LB041 | Analysis of Phospholipids (Inertsil ODS-4) | Inertsil ODS-4 |
| LB042 | Analysis of 18Drugs(InertSustain C18 2um) | InertSustain C18 |
| LB043 | Analysis of 18Drugs(InertSustain C18 HP) | InertSustain C18 |
| LB044 | Analysis of Pyridine derivatives (InertSustain C8) | InertSustain C8 |
| LB045 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
| LB046 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
| LB047 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
| LB048 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
| LB049 | Analysis of Pioglitazone(Inertsil ODS-4) | Inertsil ODS-4 |
| LB050 | Analysis of Pioglitazone(Inertsil ODS-4) | Inertsil ODS-4 |
| LB051 | Analysis of Amlodipine (Inertsil ODS-4) | Inertsil ODS-4 |
| LB052 | Analysis of Valsartan (Inertsil ODS-4) | Inertsil ODS-4 |
| LB053 | Analysis of Alkylbenzene sulfonate (Inertsil ODS-3) | Inertsil ODS-3 |
| LB054 | Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia) | InertSustain C8 |
| LB055 | Analysis of Olopatadine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) | InertSustain C8 |
| LB056 | Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) | InertSustain C8 |
| LB057 | Analysis of Acetylcysteine (Under the Condition of Japanese Pharmacopoeia 16) | Inertsil ODS-4 |
| LB058 | Analysis of Amlodipine Besilate (Under the Condition of Japanese Pharmacopoeia, Amlodipine Besilate Tablets) | InertSustain C18 |
| LB059 | Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia) | Inertsil C8-4 |
| LB060 | Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine Fumarate Tablets) | Inertsil C8-4 |
| LB061 | Analysis of Sarpogrelate Hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) | Inertsil ODS-2 |
| LB062 | Analysis of Cetiridine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Cetiridine hydrochloride Tablets) | Inertsil C8-3 |
| LB063 | Analysis of Tranilast (InertSustain C18)(Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB064 | Analysis of Tranilast (Inertsil ODS-4)(Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB065 | Analysis of Brotizolam(Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C8 |
| LB066 | Analysis of Mosapride Citrate Tablets (Under the Condition of Japanese Pharmacopoeia 16) | InertSustain C18 |
| LB067 | Analysis of Aripiprazole | InertSustain C18 |
| LB068 | Analysis of Olmesartan medoxomil | InertSustain C18 |
| LB069 | Analysis of Rosuvastatin Calcium | InertSustain C18 |
| LB070 | Analysis of 13 drugs for NSAIDs | InertSustain C18 |
| LB071 | Analysis of Esomeprazol (InertSustain C18) | InertSustain C18 |
| LB072 | Analysis of Ezetimibe (Inertsil C8-4) | Inertsil C8-4 |
| LB073 | Analysis of Irbesartan (Inertsil ODS-4) | Inertsil ODS-4 |
| LB074 | Analysis of Rabeprazol (InertSustain C18) | InertSustain C18 |
| LB075 | Analysis of Venlafaxine (InertSustain C18) | InertSustain C18 |
| LB076 | Analysis of 4 Pesticides (InertSustain C18) | InertSustain C18 |
| LB077 | Analysis of 4 Pesticides (InertSustain Phenyl) | InertSustain Phenyl |
| LB078 | Analysis of 4 Pesticides (Inertsil ODS-4) | Inertsil ODS-4 |
| LB079 | Analysis of 4 Pesticides (Inertsil ODS-3) | Inertsil ODS-3 |
| LB081 | Analysis of Fucoxanthin (Inertsil ODS-3) | Inertsil ODS-3 |
| LB082 | Analysis of Sertraline hydrochloride (Under the Condition of European Pharmacopoeia 7.0) | Inertsil ODS-3 |
| LB083 | Analysis of Ranitidine hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) | ODS |
| LB084 | Analysis of Olmesartan medoxomil (Under the Condition of United States Pharmacopeia 35-NF30) | InertSustain C18 |
| LB085 | Analysis of Olmesartan medoxomil (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-2 |
| LB086 | Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB087 | Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia, Naftopidil Tablets) | InertSustain C18 |
| LB088 | Analysis of Pre-column Derivatized Amino Acids | Inertsil ODS-4 |
| LB089 | Analysis of Phenylenediamine | Inertsil ODS-3 |
| LB091 | Analysis of Sinigrin (Inertsil ODS-3) | Inertsil ODS-3 |
| LB092 | Analysis of Edaravone (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB093 | Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
| LB094 | Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
| LB095 | Analysis of Edaravone Injection (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB096 | Analysis of p-Hydroxybenzoic acid methyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB097 | Analysis of p-Hydroxybenzoic acid ethyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB098 | Analysis of p-Hydroxybenzoic acid n-propyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB099 | Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB100 | Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |